ClinicalTrials.Veeva

Menu

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Novartis logo

Novartis

Status and phase

Completed
Phase 4

Conditions

Diastolic Dysfunction, Symptomatic Heart Failure

Treatments

Drug: valsartan

Study type

Interventional

Funder types

Industry

Identifiers

NCT00171106
CVAL489B2401

Details and patient eligibility

About

This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptomatic diastolic heart failure
  • Breathlessness with physical exertion

Exclusion criteria

  • Uncontrolled hypertension
  • Asthma, COPD, or abnormal lung function
  • History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
  • Liver, kidney, or pancreas disease
  • Allergy to valsartan

Other protocol-defined exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems